Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naive Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

被引：0

作者：

Mascarenhas, John ^{[1
]}

Kremyanskaya, Marina ^{[2
]}

Patriarca, Andrea ^{[3
,4
]}

Gupta, Vikas ^{[5
]}

Palandri, Francesca ^{[6
]}

Devos, Timothy ^{[7
,8
]}

Rampal, Raajit K. ^{[9
]}

Talpaz, Moshe ^{[10
]}

Vannucchi, Alessandro ^{[11
]}

Kuykendall, Andrew ^{[12
]}

Kiladjian, Jean-Jacques ^{[13
]}

Verstovsek, Srdan ^{[14
]}

Mesa, Ruben ^{[15
]}

Colak, Gozde ^{[16
]}

Li, Qing ^{[17
]}

Klein, Sandra ^{[16
]}

Harrison, Claire ^{[18
]}

机构：

[1] Icahn Sch Med Mt Sinai, Dept Hematol & Med Oncol, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA

[3] Univ Piemonte Orientale, Dept Translat Med, Hematol Unit, Novara, Italy

[4] AOU Maggiore Carite, Novara, Italy

[5] Univ Toronto, Dept Med, Toronto, ON, Canada

[6] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seregnoli, Bologna, Italy

[7] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven, Belgium

[8] Katholieke Univ Leuven, Rega Inst, Lab Mol Immunol, Leuven, Belgium

[9] Mem Sloan Kettering Canc Ctr, Ctr Hematol Malignancies, 1275 York Ave, New York, NY 10021 USA

[10] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA

[11] Univ Florence, Azienda Osped Univ Careggi, Florence, Italy

[12] H Lee Mofitt Canc Ctr, Dept Malignant Hematol, Tampa, FL USA

[13] Univ Paris, Hop St Louis, Paris, France

[14] MD Anderson Canc Ctr, Houston, TX USA

[15] UT Hlth San Antonio MD Anderson Canc Ctr, Mays Canc Ctr, San Antonio, TX USA

[16] Constellat Pharmaceut Inc, Boston, MA USA

[17] MorphoSys US Inc, Boston, MA USA

[18] Guys & St Thomas NHS Fdn Trust, London, England

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158147

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[11] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment-Naive Myelofibrosis Patients
Mascarenhas, John
Harrison, Claire
Luptakova, Katarina
Wang, Jing
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Humphrey, Jeffrey
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S363 - S363
[12] A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF).
Kremyanskaya, Marina
Hoffman, Ronald
Mascarenhas, John
Bose, Prithviraj
Gupta, Vikas
Schiller, Gary J.
Liew, Elena
Lebedinsky, Claudia
Senderowicz, Adrian Mario
Mertz, Jennifer
Trojer, Patrick
Verstovsek, Srdan
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[13] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients
Mascarenhas, John
Harrison, Claire
Luptakova, Katarina
Christo, Jessica
Wang, Jing
Mertz, Jennifer A.
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Senderowicz, Adrian
Humphrey, Jeffrey S.
Verstovsek, Srdan
BLOOD, 2020, 136
[14] Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data
Verstovsek, Srdan
Salama, Mohamed E.
Mascarenhas, John
Talpaz, Moshe
Mesa, Ruben A.
Vannucchi, Alessandro
Rampal, Raajit
Oh, Stephen T.
Olteanu, Horatiu
Chiu, April
Chen, Dong
Hanson, Curtis A.
Curto-Garcia, Natalia
Taverna, Pietro
Cui, Jike
Zavidij, Oksana
Chen, Zehua
Colak, Gozde
Efuni, Sergey
Keller, Patricia J.
Trojer, Patrick
Harrison, Claire N.
BLOOD, 2021, 138
[15] CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, AS "ADD-ON" TO RUXOLITINIB, IN ADVANCED MYELOFIBROSIS PATIENTS WITH SUBOPTIMAL RESPONSE: UPDATE OF MANIFEST PHASE 2 STUDY
Patriarca, A.
Verstovsek, S.
Mascarenhas, J.
Kremyanskaya, M.
Hoffman, R.
Rampal, R.
Gupta, V.
Talpaz, M.
Granacher, N.
Leber, B.
Vannucchi, A.
Bose, P.
McMullin, M.
Sirhan, S.
Ribrag, V.
Palandri, F.
Passamonti, F.
Tomassetti, S.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Harrison, C.
HAEMATOLOGICA, 2021, 106 (10) : 63 - 63
[16] CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as "add-on" to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: update of MANIFEST phase 2 study
Somervaille, Tim
Verstovsek, Srdan
Mascarenhas, John
Kremyanskaya, Marina
Hoffman, Ronald
Rampal, Raajit
Gupta, Vikas
Talpaz, Moshe
Granacher, Nikki
Leber, Brian
Kiladjian, Jean-Jacques
Vannucchi, Alessandro
Bose, Prithviraj
McMullin, Mary
Sirhan, Shireen
Ribrag, Vincent
Prejzner, Witold
Foltz, Lynda
Patriarca, Andrea
Lambert, Jonathan
Luptakova, Katarina
Christo, Jessica
Wang, Jing
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Harrison, Claire
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 98 - 99
[17] Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naive Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
Mascarenhas, John
Rampal, Raajit K.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen T.
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Lavie, David
Harris, Morgan
Kays, Sarah-Katharina
Jegg, Anna Maria
Wu, Manlei
Brown, Barbara
Harrison, Claire
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S416 - S417
[18] MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF CPI 0610 AND RUXOLITINIB VS. PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-TREATMENT-NAIVE MYELOFIBROSIS PATIENTS
Passamonti, F.
Palandri, F.
Mascarenhas, J.
Harrison, C.
Patriarca, A.
Vannucchi, A.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Humphrey, J.
Verstovsek, S.
HAEMATOLOGICA, 2021, 106 (10) : 81 - 82
[19] MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis
Mascarenhas, John
Kremyanskaya, Marina
Hoffman, Ronald
Bose, Prithviraj
Talpaz, Moshe
Harrison, Claire N.
Gupta, Vikas
Leber, Brian
Sirhan, Shireen
Kabir, Sujan
Senderowicz, Adrian
Shao, James
Mertz, Jennifer
Trojer, Patrick
Verstovsek, Srdan
BLOOD, 2019, 134
[20] CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, as monotherapy in advanced myelofibrosis patients refractory/intolerant to jak inhibitor: update from phase 2 manifest study
Drummond, Mark
Talpaz, Moshe
Rampal, Raajit
Verstovsek, Srdan
Kiladjian, Jean-Jacques
Vannucchi, Alessandro
Kremyanskaya, Marina
Schiller, Gary
Patriarca, Andrea
Van Gorkom, Gwendolyn
Bose, Prithviraj
Granacher, Nikki
Scandura, Joseph
Prejzner, Witold
Ribrag, Vincent
Oh, Stephen
Hoffman, Ronald
Luptakova, Katarina
Christo, Jessica
Wang, Jing
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Mascarenhas, John
Harrison, Claire
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 59 - 60

← 1 2 3 4 5 →